PSEN1 and hereditary elliptocytosis: For studying the therapeutic effect in short-term administration, female APP/PS1 mice were administrated by gavage with vehicle (n = 8), HE-A or HE-S (30 mg·kg−1·day−1, n = 8 for each group) at 5 months of age for 30 days.